Literature DB >> 8103877

Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids.

F E Simons1, M P Persaud, C A Gillespie, M Cheang, E P Shuckett.   

Abstract

The prevalence of posterior subcapsular cataracts in young patients receiving inhaled glucocorticoids for treatment of chronic asthma is unknown. In a cross-sectional study, slit-lamp examinations were done on 95 consecutive young patients who were taking inhaled beclomethasone or budesonide. No posterior subcapsular cataracts were found. The median age of the patients was 13.8 (range 5.8-24.8). The median dose of inhaled beclomethasone or budesonide was 750 micrograms/day (range 300-2000), or 12.9 micrograms/kg per day (range 7.5-34.2). The median duration of treatment was 5 years (range 1-15). 77% of the patients had not used oral glucocorticoids in the year preceding the examination. This study suggests that routine screening for posterior subcapsular cataracts in this patient population is not warranted.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103877     DOI: 10.1016/0140-6736(93)91541-s

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  19 in total

Review 1.  Asthma and other recurrent wheezing disorders in children (chronic).

Authors:  Stephen William Turner; Amanda Jane Friend; Augusta Okpapi
Journal:  BMJ Clin Evid       Date:  2012-01-18

Review 2.  Inhaled corticosteroids and cataract: prevalence, prevention and management.

Authors:  R G Cumming; P Mitchell
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

3.  Risk of cataracts in the Childhood Asthma Management Program Cohort.

Authors:  Hengameh H Raissy; Alice L Sternberg; Paul Williams; Aaron Jacobs; H William Kelly
Journal:  J Allergy Clin Immunol       Date:  2010-08       Impact factor: 10.793

Review 4.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 5.  Safety of inhaled corticosteroids in the treatment of persistent asthma.

Authors:  Stephen P Peters
Journal:  J Natl Med Assoc       Date:  2006-06       Impact factor: 1.798

Review 6.  Ocular toxicity of systemic asthma and allergy treatments.

Authors:  Leonard Bielory
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

7.  Erratum to: Safety Considerations of Inhaled Corticosteroids in the Elderly.

Authors:  Salvatore Battaglia; Irene Cardillo; Federico Lavorini; Mario Spatafora; Nicola Scichilone
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

8.  Nasal steroid perspective: knowledge and attitudes.

Authors:  Cemal Cingi; Murat Songu
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-21       Impact factor: 2.503

Review 9.  Inhaled corticosteroids in the long-term management of patients with chronic obstructive pulmonary disease.

Authors:  Don D Sin; S F Paul Man
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Adverse Effects of Nonsystemic Steroids (Inhaled, Intranasal, and Cutaneous): a Review of the Literature and Suggested Monitoring Tool.

Authors:  Ratika Gupta; Luz S Fonacier
Journal:  Curr Allergy Asthma Rep       Date:  2016-06       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.